sábado, 13 de octubre de 2018

Celgene shutters blood cancer trial, possibly dimming hopes for promising therapy

Celgene shutters blood cancer trial, possibly dimming hopes for promising therapy

Daily Recap

STAT Plus: Early blood cancer trial is shuttered, possibly dimming hopes for promising therapy

By DAMIAN GARDE


ED UTHMAN/CREATIVE COMMONS
The experimental drug was part of a new class of therapies meant to kill tumors by blocking the protein, which is called CD47.

No hay comentarios:

Publicar un comentario